PRNewsWire
03 Sept 2026, 20:54 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA has extended the PDUFA target action date for Capricor's lead therapy, deramiocel, from August 22, 2026, to November 22, 2026. — Regulatory delays for a lead product candidate typically create uncertainty and defer potential revenue streams, often leading to downward price pressure.
-0.60Capricor is facing a securities class action lawsuit alleging management misrepresented trial endpoints and undisclosed modifications between December 2025 and July 2026. — Ongoing securities litigation creates legal liability risks and suggests potential transparency issues with corporate governance.
-0.40Capricor has requested to pivot the indication of deramiocel to focus solely on upper limb function following a turbulent July 2026 Advisory Committee meeting. — Narrowing the target indication usually reduces the total addressable market (TAM) and indicates that broader efficacy claims were likely unsupported.
-0.30Continue reading
6 related stories
Search tags
Which stocks this story touches
The company is facing a securities class action lawsuit and an FDA review extension for its lead investigational cell therapy.
The company is mentioned as being subject to a class action lawsuit for investors who suffered losses.
The company is the subject of a securities fraud class action lawsuit alert.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
